Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial

1. Garber, A.J.
2. King, A.B.
3. Del Prato, S.
4. Sreenan, S.
5. Balci, M.K.
6. Muñoz-Torres, M.
7. Rosenstock, J.
8. Endahl, L.A.
9. Ocampo Francisco, A.M.
10. Hollander, P.